Compare Neurocrine Biosciences Inc (NBIX) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs NetEase Inc — how do they compare? Neurocrine Biosciences Inc trades at $156.22 (market cap $16.46B), while NetEase Inc trades at $127.56 (market cap $82.75B). The key difference: NetEase Inc is far larger — about 5× Neurocrine Biosciences Inc's market cap, and NetEase Inc pays a 2.36% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NTES | |
|---|---|---|
Market Cap | $16.46B | $82.75B |
Sector | Health | Media |
52-Week High | $185.50 | $159.34 |
52-Week Low | $123.10 | $109.26 |
Enterprise Value | $16.48B | $59.05B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.
Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.
NetEase (NTES) trades at $124.08, down 6.99% over the past 24 hours, with a P/E ratio of 16.31 and strong profitability metrics including a 29.84% net income margin. Recent earnings show mixed results with a Q1 2026 beat but Q3 and Q4 2025 misses. Technical indicators suggest a bullish trend with support at $126 and resistance at $129. The company maintains robust cash flow from operations of $50.74 billion in 2025 and recently announced a $0.72 dividend for H1 2026.
Outlook remains positive with 82% analyst buy ratings and a projected 34.7% upside potential. Key opportunities include international expansion and strong free cash flow generation, while risks involve competitive pressures in gaming and regulatory uncertainties in China. Revenue growth is steady, reaching $112.63 billion in 2025, supporting a solid fundamental base for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
